| Drug Name |
Atosiban |
| Drug ID |
BADD_D00185 |
| Description |
Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women. |
| Indications and Usage |
Atosiban is indicated for use in delaying imminent pre-term birth in pregnant adult women with:
- regular uterine contractions of at least 30 s duration at a rate of at least 4 per 30 min
- a cervical dilation of 1-3cm (0-3cm for nulliparas) and effacement of at least 50%
- a gestational age of 24-33 weeks
- a normal fetal heart rate |
| Marketing Status |
approved; investigational |
| ATC Code |
G02CX01 |
| DrugBank ID |
DB09059
|
| KEGG ID |
D03008
|
| MeSH ID |
C047046
|
| PubChem ID |
5311010
|
| TTD Drug ID |
D0D8XY
|
| NDC Product Code |
Not Available |
| UNII |
081D12SI0Z
|
| Synonyms |
atosiban | (Mpa(1)-D-Tyr(Et)(2)-Thr(4)-Orn(8))-oxytocin | oxytocin, 1-deamino-O-ethyltyrosyl(2)-threonyl(4)-ornithine(8)- | oxytocin, 1-deamino-(O-Et-Tyr)(2)-Thr(4)-Orn(8)- | (Mpa(1),D-Tyr(Et)2,Thr(4),Orn(8))oxytocin | 1-deamino-2-Tyr(OEt)-4-Thr-8-Orn-oxytocin | RWJ-22164 | RWJ 22164 | ORF-22164 | ORF 22164 |
